Ascendis Pharma (ASND) Stock
Fundamentals
Compare with ASND
Recent news

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND

Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S Q2 Earnings Call Highlights
ASND

Why Crinetics Stock Soared 99% This Week
Why Crinetics Stock Soared 99% This Week
ASND

Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
ASND
Technical indicators
- RSI 14
- 36.58
- MACD 12/26/9
- -7.43
- EMA 9 of MACD
- -6.73
- MACD histogram
- -0.70
- SMA 50
- $247.63
- Price below SMA 50
- EMA 50
- $243.67
- Price below EMA 50
- SMA 200
- $235.76
- Price below SMA 200
- EMA 200
- $233.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 13 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.76 for this quarter. The company has not yet shared when it is announcing earnings.
Latest news

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND

Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S Q2 Earnings Call Highlights
ASND

Why Crinetics Stock Soared 99% This Week
Why Crinetics Stock Soared 99% This Week
ASND

Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
ASND

Ascendis wins U.S. approval for therapy for children with dwarfism
Ascendis wins U.S. approval for therapy for children with dwarfism
ASND

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
ASND

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
ASND

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
ASND

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
ASND

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
ASND
About Ascendis Pharma
Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, endocrinology rare disease product candidates in clinical development, and multiple preclinical programs in oncology, our second therapeutic area.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | 1960 |
| Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | 1974 |
| Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | 1971 |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer | 1970 |
| Mr. Chad Fugure | Vice President of Investor Relations | — |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | 1961 |
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | 1979 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | 1969 |
| Ms. Sherrie Lynn Glass | Chief Business Officer | 1972 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 36.58
- MACD 12/26/9
- -7.43
- EMA 9 of MACD
- -6.73
- MACD histogram
- -0.70
- SMA 50
- $247.63
- Price below SMA 50
- EMA 50
- $243.67
- Price below EMA 50
- SMA 200
- $235.76
- Price below SMA 200
- EMA 200
- $233.80
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 6, 2026. Technical data, not a recommendation.
Analyst views
13 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $273.00
- Average
- $314.00
- High
- $344.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.4 | -14.3 | -5.0 | |||||||||
| 2022 | -10.4 | -7.3 | +7.8 | -21.3 | -7.2 | +9.6 | -7.6 | +6.6 | +15.9 | +15.7 | +5.4 | +0.3 |
| 2023 | +2.8 | -10.0 | -5.3 | -3.9 | +0.3 | +1.5 | +2.3 | +7.0 | -4.7 | -2.0 | +10.6 | +21.0 |
| 2024 | +1.9 | +4.3 | -0.9 | -8.9 | -4.2 | +0.8 | -0.4 | +1.4 | +10.9 | -16.2 | +8.6 | +3.1 |
| 2025 | -5.3 | +25.2 | +2.6 | +12.6 | -2.8 | -1.8 | +0.9 | +11.3 | -0.2 | -1.2 | +5.6 | +1.1 |
| 2026 | +6.0 | +4.4 | -5.5 | +0.5 | +1.4 | +21.9 | -8.9 | +8.0 | -12.5 | -0.6 |



